A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

NCT04103905 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

CD20-positive B Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL62 Injection

Sponsor

Beijing Mabworks Biotech Co., Ltd.